GLP-1 Receptor Agonist Market

Published Aug 21, 2025

Length 170 Pages

SKU # CMI20399595

Description

GLP 1 receptor agonists are an important class of anti diabetic drugs for the treatment of type 2 diabetes. These mimic the effects of endogenous glucagon like peptide 1 (GLP 1), a peptide hormone released after eating which stimulates insulin secretion and suppresses glucagon secretion in a glucose dependent manner. By binding to and activating the GLP 1 receptor, these drugs induce insulin secretion, inhibit glucagon release, suppress appetite and promote weight loss in diabetic patients. Their superior glucose control efficacy and low risk of hypoglycemia as compared to other classes make them an attractive option, thus, driving the market growth.

Market Dynamics

Global GLP 1 receptor agonist market growth is driven by growing prevalence of diabetes worldwide coupled with the superior therapeutic efficacy of GLP 1 receptor agonists. Rising levels of obesity can increase the risk of type 2 diabetes, thus, boosting demand for more effective medical treatments. However, high development costs and stringent regulatory approvals can hamper the market growth. New product launches featuring improved formulations, flexible dosing options, longer duration of action and multi indication usage can offer growth opportunities. Manufacturers are investing in R&D to expand clinical indications and develop oral versions of these drugs to improve patient convenience.

Key Features of the Study

This report provides in depth analysis of the global GLP 1 receptor agonist market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global GLP 1 receptor agonist market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Novo Nordisk A/S, Eli Lilly and Company and Sanofi.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up gradation, market expansion, and marketing tactics.
Global GLP 1 receptor agonist market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global GLP 1 receptor agonist market.

Market Segmentation

Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
Exenatide
Liraglutide
Dulaglutide
Lixisenatide
Albiglutide
Semaglutide
Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
Parenteral
Oral
Application Insights (Revenue, USD Bn, 2020 - 2032)
Type 2 Diabetes Mellitus
Obesity
Liver Cirrhosis
Non-alcoholic Steatohepatitis
Others
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Insights (Revenue, USD Bn, 2020 - 2032)
North America
U.S.
Canada
Latin America
Brazil
Argentina
Mexico
Rest of Latin America
Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
GCC Countries
Israel
Rest of Middle East
Africa
South Africa
North Africa
Central Africa
Key Players Insights
Eli Lilly and Company
Sanofi
Novo Nordisk A/S
AstraZeneca
Perrigo Company PLC
3M Company
Bausch Health
Taro Pharmaceutical Industries
Novan Inc.
Serum Institute of India Pvt. Ltd.
Orgenesis biotech company
Verrica Pharmaceuticals
AbbVie Inc.
Lee's Pharmaceutical Holdings Ltd.
Cassiopea
Glenmark Pharmaceuticals

1. Research Objectives and Assumptions: Research Objectives; Assumptions; Abbreviations
2. Market Purview: Report Description; Market Definition and Scope; Executive Summary; Market Snapshot, By Drug Class; Market Snapshot, By Route of Administration; Market Snapshot, By Application; Market Snapshot, By Distribution Channel; Market Snapshot, By Region
3. Market Dynamics, Regulations, and Trends Analysis: Market Dynamics; Drivers; Restraints; Opportunities; Impact Analysis; Market Trends; Key Developments; Regulatory Scenario; Acquisitions and Partnerships Scenario; Funding and Investments; PEST Analysis; Porter’s Analysis
4. GLP-1 Receptor Agonist Market, By Drug Class, 2020 – 2032, (USD Bn): Overview; Market Share Analysis, 2025 and 2032 (%); Y-o-Y Growth Analysis, 2021– 2032; Segment Trends; Exenatide; Overview; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn); Liraglutide; Overview; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn); Dulaglutide; Overview; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn); Lixisenatide; Overview; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn); Albiglutide; Overview; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn); Semaglutide; Overview; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
5. GLP-1 Receptor Agonist Market, By Route of Administration, 2020 – 2032, (USD Bn): Overview; Market Share Analysis, 2025 and 2032 (%); Y-o-Y Growth Analysis, 2021 – 2032; Segment Trends; Parenteral; Overview; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn); Oral; Overview; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
6. GLP-1 Receptor Agonist Market, By Application, 2020 – 2032, (USD Bn): Overview; Market Share Analysis, 2025 and 2032 (%); Y-o-Y Growth Analysis, 2021 – 2032; Segment Trends; Type 2 Diabetes Mellitus; Overview; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn); Obesity; Overview; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn); Liver Cirrhosis; Overview; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn); Non-alcoholic Steatohepatitis; Overview; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn); Others; Overview; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
7. GLP-1 Receptor Agonist Market, By Distribution Channel, 2020 – 2032, (USD Bn): Overview; Market Share Analysis, 2025 and 2032 (%); Y-o-Y Growth Analysis, 2021 – 2032; Segment Trends; Hospital Pharmacies; Overview; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn); Retail Pharmacies; Overview; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn); Online Pharmacies; Overview; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (USD Bn)
8. GLP-1 Receptor Agonist Market, By Region, 2020 – 2032, (USD Bn): Introduction; Market Share Analysis, By Region, 2025 and 2032 (%); Y-o-Y Growth Analysis, For Region, 2021–2032; Regional Trends; North America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn); Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2032, (USD Bn); U.S.; Canada; Latin America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn); Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2032, (USD Bn); Brazil; Mexico; Argentina; Rest of Latin America; Europe; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn); Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2032, (USD Bn); U.K.; Germany; Italy; France; Spain; Russia; Rest of Europe; Asia Pacific; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn); Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2032, (USD Bn); China; India; Japan; ASEAN; Australia; South Korea; Rest of Asia Pacific; Middle East; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn); Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2032, (USD Bn); GCC; Israel; Rest of Middle East; Africa; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn); Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn); Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 – 2032, (USD Bn); North Africa; Central Africa; South Africa
9. Competitive Landscape: Company Profiles; Eli Lilly and Company; Company Highlights; Method Portfolio; Key Highlights; Financial Performance; Market Strategies; Sanofi; Company Highlights; Method Portfolio; Key Highlights; Financial Performance; Market Strategies; Novo Nordisk A/S; Company Highlights; Method Portfolio; Key Highlights; Financial Performance; Market Strategies; AstraZeneca; Company Highlights; Method Portfolio; Key Highlights; Financial Performance; Market Strategies; Perrigo Company PLC; Company Highlights; Method Portfolio; Key Highlights; Financial Performance; Market Strategies
3M Company: Company Highlights; Method Portfolio; Key Highlights; Financial Performance; Market Strategies; Bausch Health; Company Highlights; Method Portfolio; Key Highlights; Financial Performance; Market Strategies; Taro Pharmaceutical Industries; Company Highlights; Method Portfolio; Key Highlights; Financial Performance; Market Strategies; Novan Inc.; Company Highlights; Method Portfolio; Key Highlights; Financial Performance; Market Strategies; Serum Institute of India Pvt. Ltd.; Company Highlights; Method Portfolio; Key Highlights; Financial Performance; Market Strategies; Orgenesis biotech company; Company Highlights; Method Portfolio; Key Highlights; Financial Performance; Market Strategies; Verrica Pharmaceuticals; Company Highlights; Method Portfolio; Key Highlights; Financial Performance; Market Strategies; AbbVie Inc.; Company Highlights; Method Portfolio; Key Highlights; Financial Performance; Market Strategies; Lee's Pharmaceutical Holdings Ltd; Company Highlights; Method Portfolio; Key Highlights; Financial Performance; Market Strategies; Cassiopea; Company Highlights; Method Portfolio; Key Highlights; Financial Performance; Market Strategies; Glenmark Pharmaceuticals; Company Highlights; Method Portfolio; Key Highlights; Financial Performance; Market Strategies
10. Analyst Recommendations: Wheel of Fortune; Analyst View; Coherent Opportunity Map
11. References and Research Methodology: References; Research Methodology; About Us and Sales Contact; *Browse 32 market data tables and 28 figures on GLP-1 Receptor Agonist Market” - Global forecast to 2032

Pricing

Currency Rates

Single User Email from Publisher $4,500
Site License Fulfilled by Publisher $7,000
Global Site License Email from Publisher $10,000

How Do Licenses Work?

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now